Neurology Clinical Trials Market Current Scenario and Industry Growth Forecast with Major Key Players data by 2032 | FMI

 In 2021, the global Neurology Clinical Trials Market was estimated to be worth approximately US$ 5.4 billion. With a CAGR of 6.3% over the next ten years, the market is expected to be worth nearly US$ 10.5 billion by the end of 2032. Over the forecasted period, the neurology clinical trials market is expected to grow at an absolute dollar opportunity of US$ 4.8 billion.Huntington’s disease occurs in every 2.7 per 100,000 habitats worldwide. Egypt contributes to the highest number of people suffering from Huntington’s disease with 21 of every 100,000 individuals.

Request a Sample Report with Table of Content (ToC) @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15859

US to dominate the neurology clinical trials Market throughout the Analysis Period

The US generated the highest revenue in the neurology clinical trials market in 2021.  Revenue through neurology clinical trials in the U.S. grew at a CAGR of 5.3% during 2017-2021. An increase in life expectancy and a rise in neurological disorders in the U.S. is driving the need to expand neurology clinical trials. Support from government agencies and leading pharmaceutical companies like Biogen are leading the market with anticipated revenue growth of 6.6% CAGR over the forecasted period set between 2021 and 2032.

Neurology Clinical Trials Market: Competition Insights

At present, health organizations and pharmaceutical companies are largely aiming at expanding their manufacturing facilities, investing in R&D, and inventing new drugs for the treatment of neurological disorders.

Neurological Studies are studies that aim to evaluate the safety and efficacy of new treatments or therapies for neurological disorders. These trials are conducted to gather data on the effects of these treatments on patients with various neurological conditions, including Alzheimer's disease, multiple sclerosis, Parkinson's disease, epilepsy, and many others.

The key companies operating in the neurology clinical trials market include:

  • IQVIA
  • Novartis
  • Covance
  • Medpace
  • Charles River Laboratories
  • GlaxoSmithKline
  • Aurora Healthcare
  • Biogen

Some of the recent developments by key providers of neurology clinical trials are as follows:

  • In June 2022, Novartis announced the publication of Nature Medicine of Zolgensma data. The data revealed that children with spinal muscular atrophy (SMA) treated with Zolgensma were able to retain age-appropriate motor skills such as sitting, standing, and walking independently.
  • In June 2022, Biogen joined hands with Alectos Therapeutics to develop and commercialize a small molecule therapy known as AL01811, as a possible treatment for Parkinson’s disease. The collaboration will benefit Alectos with US$ 77.5 and US$ 630 Mn for development and commercial payments respectively. Moreover, Biogen will conduct responsible for regulatory costs and manufacturing once the therapy is approved for clinical settings.
  • In June 2022, Scientists at Yale University discovered that a drug developed by Bristol Myers Squibb has the ability to repair the loss of neuronal nexus known as synapse which is the key contributor to cognitive decline. The study also stated that it has the ability to restore synaptic connections in Alzheimer’s mouse models. The drug also minimized the toxic build-up of tau protein present in the brain of animals.
  • In April 2022, Novartis announced long-term data of Phase 3 ASCLEPIOS I/II trials. The data exhibited the efficacy of Kesimpta and stated that treatment of four years will reduce the risk of three and six months of confirmed disability and fewer relapses.
  • In April 2022, FDA granted Novartis, a commercial license to manufacture Zolgensma, a multi-product gene therapy with a 170,000 square-foot facility at Durham, N.C. site to test and release Zolgensma.

For more information: https://www.futuremarketinsights.com/reports/neurology-clinical-trials-market

Key Segments Covered in Neurology Clinical Trials Industry Survey

Neurology Clinical Trials Market by Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Neurology Clinical Trials Market by Study Design:

  • Interventional
  • Observational
  • Expanded access

Neurology Clinical Trials Market by Indication:

  • Epilepsy
  • Parkinson’s Disease
  • Huntington’s Disease
  • Stroke
  • Traumatic brain Injury (TBI)
  • Amyotrophic Lateral Sclerosis (ALS)
  • Muscle regeneration
  • Other Indications

Comments

Post a Comment

Popular posts from this blog

Biocomposites Market Current and Future Trends, Leading Players, Industry Segments and Regional Forecast By 2032 | Says FMI Analyst

Image
  The Global Biocomposites Market reached more than US$ 25 billion in 2021 and is predicted to increase at an amazing 16% CAGR between 2022 and 2032, reaching over US$ 128 billion by the end of 2032. Biocomposite The increased research and development efforts for composite materials and  biocomposite uses  and benefits such as recyclability, lightweight, and cost-effectiveness are driving this trend. In addition, due to the harmful nature of synthetic materials, recycling challenges, and toxic residues, the  biocomposites market size  will continue to expand throughout the predicted timetable. Request a report sample to gain comprehensive insights at: https://www.futuremarketinsights.com/reports/sample/rep-gb-14293 As per the  biocomposites market report , Germany, the United States, and Japan are among the developed countries working on boosting the usage of ecologically friendly items rather than petroleum-based products.  The European Un...
Read more

Human Immunodeficiency Virus Type 1 (HIV 1) Market Opportunity, Competitive Analysis, Future Prospects to 2033

Image
  The global Human Immunodeficiency Virus Type 1 (HIV 1) Market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. Get Full Access @ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million...
Read more

Pet Diabetes Care Devices Market Report | Size, Growth, Demand, Scope and Forecast to 2032

  The global  Pet Diabetes Care Devices Market  is expected to grow at a  6.5%  CAGR, reaching  US$ 4 billion  by 2032, up from  US$ 2 billion  in 2021. “The number of pets with diabetes, the number of adopted pets, and the number of overweight pets are all driving the market forward.” Get Full Access @ https://www.futuremarketinsights.com/reports/pet-diabetes-care-devices-market The domestication of animals is leading to a lack of insulin production in them. The limited flow of glucose to the cell can be termed diabetes. This chronic disease is a major concern for pet owners and needs to be taken care of. This concern leads to the expansion of the pet diabetes care devices market. Devices like the alphatrak blood glucose meter are in use as they help the pet owners monitor the pet’s health. The increased number of people adopting pets and then domesticating them around in their households, treating and caring for them as f...
Read more